This Top Biotech Has Surged. CEO Explains Key To Veracyte's Success.

Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.

Investors Business Daily • Jun 16, 2026

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 11, 2026

Here's Why Veracyte (VCYT) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 9, 2026

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Seeking Alpha • Jun 1, 2026

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

Business Wire • Jun 1, 2026

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.

Business Wire • May 30, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.

Business Wire • May 29, 2026

Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform

Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.

Seeking Alpha • May 28, 2026

Veracyte genomic test identifies breast cancer patients who can skip chemo

Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be ​practice-changing.

Reuters • May 27, 2026